Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
<h4>Background</h4>The importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in...
Guardado en:
Autores principales: | Grégoire Mignot, Alice Hervieu, Pierre Vabres, Sophie Dalac, Geraldine Jeudy, Blandine Bel, Lionel Apetoh, François Ghiringhelli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6081e4e3111d4195adcb82f9d1b529b5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effect of dacarbazine on CD44 in live melanoma cells as measured by atomic force microscopy-based nanoscopy
por: Huang X, et al.
Publicado: (2017) -
Transcriptomic Profiling Revealed Plexin A2 Downregulation With Migration and Invasion Alteration in Dacarbazine-Treated Primary Melanoma Cells
por: Anna Tyumentseva, et al.
Publicado: (2021) -
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Hélène Bellio, et al.
Publicado: (2021) -
Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial
por: Sebastian Krug, et al.
Publicado: (2021) -
Treatment of Advanced Metastatic Melanoma
por: Pietro Quaglino, et al.
Publicado: (2021)